The Superior Mechanical Resistance of Nexa® Vials for Improved Efficiency and Safety
Exhibitor: USIN ADVANCE CO., LTD
Date: 2025-05-22
Booth No.: M1011
JAN 8 | 2025
The Superior Mechanical Resistance of Nexa® Vials for Improved Efficiency and Safety
Executive Summary
Introduction: Ensuring the mechanical resistance of pharmaceutical glass vials is crucial for safe and efficient drug delivery. While allowing for high throughput and efficiency, the bulk Fill & Finish process exerts high level of stress on glass containers, such as glass-to-glass contact and vertical loads, which can lead to cosmetic defects and breakages. Superior vial quality mitigates the negative impact of this stress, improving filling process performance and output as well as reducing the risk of container breakage during transport.
This study aims to experimentally demonstrate the improved mechanical resistance performance of Nexa®. By comparing the 2R ISO format vial in Nexa® and Fina® platforms, this study highlights how Nexa® vials provide superior mechanical resistance, which translates into several operational benefits.
Test Methodology
Mechanical resistance was assessed using two quantitative techniques
1. Vertical Compression Test (VC): This test measures the maximum force a vial can withstand before failure when subjected to axial stress.
Figure 1: Sample before (left) and after (right) VC test.
2. Burst Test (BT): This test is performed to apply internal pressure to the glass container to obtain its maximum value of internal pressure resistance.
Figure 2: Sample before (left) and after (right) the burst test.
Both tests compared Nexa® and Fina® vials. From the results achieved (VC and BT), Nexa® vials showed consistent superior mechanical resistance.
Key Results
2R ISO vials
- In the Vertical Compression Test, Nexa® vials demonstrated an average maximum force of at least 3x Fina®.
Figure 3: Boxplot of Vertical Compression results for 2R Fina® and Nexa® vials.
- In the Burst Test, Nexa® vials are characterized by a higher mean value, in terms of maximum pressure, than Fina® vials.
Figure 4: Boxplot of Burst Test Results for 2R Fina® and Nexa® vials
Operational Benefits of Nexa® Vials - Thanks to their improved cosmetic quality and mechanical resistance, Nexa® vials provide several advantages:
01 Reduced Total Cost of Ownership (TCO): Fewer cosmetic rejections and in-line breakages reduce waste of both container and final product, which in turn lowers costs and prevents lost revenues.
02 Improved Efficiency: Nexa® vials result in fewer lines-stops, downtimes, and labor required to fix the filling line after breakage occurrence.
03 Higher Safety: The superior mechanical strength of Nexa® vials reduces the risk of harmful products being dispersed due to container breakage.
Conclusions
This study analyzed the improved mechanical resistance of Nexa® vials by comparing them to Fina® vials through vertical compression (VC) and burst test (BT). According to the results achieved, Nexa® vials have superior mechanical resistance, even 3x Fina® with regards to Vertical compression (VC).
Thanks to its improved mechanical resistance, the Nexa® vial platform offers advantages in terms of:
01 Lower risk of breakage and cosmetic rejections reducing non-quality costs, and maximizing redictivity of high-value drug products
02 Lower risk of breakage to preserve people’s safety when dealing with cytotoxic products and to guarantee container integrity during challenging freezing processes.
Nexa® vial platform is Stevanato Group next level of quality specifically designed for most of high value products such as biotech, high-value vaccines, cytotoxic and next generation drugs.
Thanks to their improved mechanical resistance and cosmetic quality Nexa® vials minimize product waste and product release into the environment during fill & finish process and final visual inspection.
Additionally, Nexa® vials ensure lower vial breakage risk at challenging temperatures during freezing and cryo treatments.
More Exhibitor's Press Release
- Honya Medical Strengthens Local Presence and Expands Toward Global Clinical Excellence HONYA MEDICAL CO., LTD. / 2025-07-30
- Honya’s MiSaver: A New Frontier in Treating Heart Damage After Heart Attacks HONYA MEDICAL CO., LTD. / 2025-07-30
- Link-Best debuted at BIO Asia Exhibition. Products attracted attention and Ignited Spark. LINK-BEST BIOSCIENCE CO., LTD. / 2025-07-30
- GoldenBiotech-Advancing First-line treatment of Meta. PanCa GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- GlobalBio: 國鼎生技-開發Antroquinonol 造福抗癌研究治療 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- GoldenBiotech Seminar:Advancing First-Line Therapy for Metastatic Pancreatic Cancer: Global Phase 3 GOLDEN BIOTECHNOLOGY CORP. / 2025-07-27
- AAVnerGene and TFBS Bioscience Announce Collaboration to Develop Innovative AAV Technology Platform TFBS BIOSCIENCE, INC. / 2025-07-25
- Visit Us at BIO Asia–Taiwan 2025! July 24 – July 27 GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-25
- GBC CellBio™ a2000 has been recognized with a 2025 Edison Award. GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-24
- GBC AI Biotech Building Officially Commissioned. GENERAL BIOLOGICALS CORPORATION (GBC) / 2025-07-24
- Your Invitation to Innovation – Booth M412 Forum MAJOR SCIENCE CO.,LTD / 2025-07-24
- Ecotek Engineering Corp.: Your Integrated Partner for Biopharma Facility and Process Equipment Solut MAJOR SCIENCE CO.,LTD / 2025-07-24
- About major science - Create life sciences research instruments through quality and innovation MAJOR SCIENCE CO.,LTD / 2025-07-24
- IOT無線連續監測系統 - 廠房、倉儲、實驗室 溫、濕度測繪 XIN TOP CORPORATION / 2025-07-24
- MarkerX Unveils MyeloTrak™ at BIO Asia, Redefining Multiple Myeloma Management with Non-invasive, Pr MARKER X CO., LTD. / 2025-07-23
- CancerFree Biotech Selected for OIST Startup Accelerator Program CANCERFREE BIOTECH LTD. / 2025-07-23
- AI Sparks a New Wave in Cancer Research: How a Taiwanese Startup Is Breaking Lab Bottlenecks and Ad CANCERFREE BIOTECH LTD. / 2025-07-23
- Transin Biomedical showcases the innovative strength of smart medical devices TRANSIN BIOMEDICAL CO., LTD. / 2025-07-23
- TaiMed Biologics Hosts Interactive Activities at BIO Asia 2025 to Promote HIV Awareness TAIMED BIOLOGICS INC. / 2025-07-22
- A Pioneer for Over Two Decades, Cell-Bio Biotechnology to Showcase Comprehensive Solutions at BioAsi CELL-BIO BIOTECHNOLOGY CO., LTD. / 2025-07-22